Polycystic ovary syndrome (PCOS) is the most common form of ovulatory dysfunction, affecting up to 8% of the population worldwide, or over 100 million women [1-3]. While subject to some controversy, it is diagnosed most frequently by the Rotterdam criteria, which includes irregular menses, laboratory or clinical evidence of hyperandrogenemia, and polycystic ovarian morphology. The diagnosis may be made if a patient has at least two of these criteria, and other possible etiologies are excluded, such as prolactin or thyroid disorders [3]. One needs only to consider the history of the diagnosis of PCOS for a glimpse of the complex nature of this disease. Up to present day, medical professionals and organizations have engaged in contentious debate as to the best way to characterize and define this heterogenous cohort of patients [4,5]. As an example, the finding of polycystic ovarian morphologyon ultrasound exists in a large proportion of women without PCOS, and may in these scenarios be normal [6,7].Thus, some have argued for more weight placed on the criteria of menstrual regularity or hyperandrogenemia [1].